<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:department>Infection Immunity and Inflammation</gtr:department><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/D725C4A8-B59A-41B2-8F38-7892AE054D8D"><gtr:id>D725C4A8-B59A-41B2-8F38-7892AE054D8D</gtr:id><gtr:firstName>Timothy</gtr:firstName><gtr:otherNames>William</gtr:otherNames><gtr:surname>Gant</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A0AFA01E-00C0-4C35-8FC9-2DB108656028"><gtr:id>A0AFA01E-00C0-4C35-8FC9-2DB108656028</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:otherNames>Richard</gtr:otherNames><gtr:surname>Barer</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/87D7FB99-B707-483D-92CC-DE87DB7284D4"><gtr:id>87D7FB99-B707-483D-92CC-DE87DB7284D4</gtr:id><gtr:firstName>Julian</gtr:firstName><gtr:otherNames>Mark</gtr:otherNames><gtr:surname>Ketley</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0801980"><gtr:id>8DB964CD-59E0-4BF9-94CC-A09E82BB6B7A</gtr:id><gtr:title>Development of a high throughput comparative microbiomics platform applied to Clostdridium difficile-associated disease.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801980</gtr:grantReference><gtr:abstractText>Cdiff is an abbreviation that has recently received much public attention as the bacterium it denotes is responsible for a hospital acquired infection that now rivals MRSA in terms of illness and deaths in the UK. The diarrhoeal disease due to Cdiff follows on from antibiotic treatment in which the large number of microbes normally resident in the human gut have been substantially disturbed. It is likely that many other human conditions are either caused by or affected by such disturbances. These collections of microbes normally resident in the gut have recently been referred to as the microbiome (the totality of microbes present at a particular location). It would be highly desirable to determine the composition of different microbiomes as this could enable us to understand and control the conditions that they influence. However, this is not possible by classical laboratory growth methods as many microbes simply cannot be cultured. DNA based analyses have recently surmounted this problem but these are largely confined to small scale studies applied to samples from a few individuals as they demand enormous financial and computing resources. To fully recognize the influence of different microbiomes on human health and disease we need to develop means of determining and comparing their compositions on a large scale involving samples from many individuals. We have established an economic high throughput approach that will provide microbiomic signatures from substantial sample sets. Through this project we aim to complete the development process and establish our approach for large scale application to clinical samples. Within the programme we will make initial analyses of the microbiome associated with Cdiff infection. These have the potential to identify organisms that may be necessary for humans to resist Cdiff infection and therefore a potential means of protection. A more certain outcome is the validation of an approach that will be a resource for all researchers wishing to make large scale microbiomic determinations and comparisons. Such analyses have clear potential to impact on Cdiff disease and many other infective and non-infective conditions.</gtr:abstractText><gtr:technicalSummary>Clostridium difficile associated diarrhoea (CDAD) is one of many human conditions in which the complex assembly of microorganisms at a particular location in the body appears to be a key determinant of susceptibility and robust response to treatment. Such assemblies or microbiomes occupy particular niches in the body and can be viewed as equivalent to accessory organs in the body with a remarkably diverse and powerful metabolic processing capacity. The advent of molecular techniques has rendered the hitherto insurmountable task of characterizing of microbiomes feasible. However, in human population studies, both the clone library sequencing and direct metagenomics approaches to achieving this are too resource and computing intensive to be applied to sample sets of sufficient size to achieve statistical validity. Here we aim to concert and validate our preliminary studies on a reverse microarray methodology based around arraying 16S rDNA clone libraries derived from clinical samples as probes and interrogating them with a set of tester oligonucleotides. In one step the approach achieves a comparison between the sample sets and provides an immediate readout of the taxa that are constant and distinct between the test groups. Moreover, the approach also reveals non-hybridising clones that may contain sequences from previously unknown organisms. In contrast to the established methodologies in which much resource is consumed by repetitive analysis of numerically dominant organisms, this approach allows sequencing to be focussed on key areas of the microbiome that reflect important constant and variable components relating to the human populations to be studied. We will synergistically combine our array strategy with state of the art pyro-sequencing to enable strategy development and more detailed microbiome determinations by refined iteration. Through this intensive technical development we will compare the faecal microbiomes of healthy individuals with those from patients with and recovered from CDAD and non CD antibiotic associated diarrhoea. While this small scale analysis has the potential to reveal major differences between these groups, our primary aim is to establish and validate an array platform for major clinical studies in this area. This outcome will not only contribute to our understanding of CDAD but will also provide a generic tool for microbiomic studies within and beyond biomedical applications.</gtr:technicalSummary><gtr:fund><gtr:end>2011-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>405769</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Microbiomics</gtr:description><gtr:id>F9C548DF-6AA9-4760-A3AC-9D120B4E315D</gtr:id><gtr:impact>Outputs in preparation</gtr:impact><gtr:outcomeId>545bdaa219b699.92150847-1</gtr:outcomeId><gtr:partnerContribution>They are supporting the bioinformatic analyses</gtr:partnerContribution><gtr:piContribution>In collaboration with Professor Chris Birightling (Leicester) we have performed microbiomic analyses on over 700 on serial sputum samples from patients with COPD. These track through exacerbation and recovery. We have produced microbiomic profiles from these samples from 16S rDNA amplicons sequences by Roche 454 HTS.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>296000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Wellcome Trust Bloomsbury Centre</gtr:department><gtr:description>Clinical Research Training Fellowship</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>107302/Z/15/Z</gtr:fundingRef><gtr:id>782430B0-85C9-4C4D-8187-1B0218CF2FAF</gtr:id><gtr:outcomeId>58bd6bd6075040.82223646</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>71A75E19-D511-4C90-97BC-7C0FBC462BEE</gtr:id><gtr:title>Microbiome balance in sputum determined by PCR stratifies COPD exacerbations and shows potential for selective use of antibiotics.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/34c77e1a7408f6a73781a3fde5978afa"><gtr:id>34c77e1a7408f6a73781a3fde5978afa</gtr:id><gtr:otherNames>Haldar K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5a2fd5f38996f3.14383175</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EA5C6061-1296-44CE-B78B-B22984C57D9E</gtr:id><gtr:title>Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/687fdae1c333df95f5a469062bd96fdc"><gtr:id>687fdae1c333df95f5a469062bd96fdc</gtr:id><gtr:otherNames>Bafadhel M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>pm_16537_27_21680942</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D32CFAA3-28C3-4B67-B408-F0C3A4A6A060</gtr:id><gtr:title>Systemic and pulmonary inflammation is independent of skeletal muscle changes in patients with chronic obstructive pulmonary disease.</gtr:title><gtr:parentPublicationTitle>International journal of chronic obstructive pulmonary disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba4addc1a896e7564698370d1fb5e822"><gtr:id>ba4addc1a896e7564698370d1fb5e822</gtr:id><gtr:otherNames>Barker BL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1176-9106</gtr:issn><gtr:outcomeId>545be0c16111f6.84265719</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9AA1C9F2-F373-420F-AFB9-7319A60C2292</gtr:id><gtr:title>Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/687fdae1c333df95f5a469062bd96fdc"><gtr:id>687fdae1c333df95f5a469062bd96fdc</gtr:id><gtr:otherNames>Bafadhel M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>pm_16537_27_22447964</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7BB46F40-88C1-4C4A-BFA3-891233CE52E3</gtr:id><gtr:title>Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD.</gtr:title><gtr:parentPublicationTitle>Chest</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/687fdae1c333df95f5a469062bd96fdc"><gtr:id>687fdae1c333df95f5a469062bd96fdc</gtr:id><gtr:otherNames>Bafadhel M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0012-3692</gtr:issn><gtr:outcomeId>pm_16537_27_21030489</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7FD942A7-101D-446C-84AE-5F4E48C6C3EE</gtr:id><gtr:title>Lung microbiome dynamics in COPD exacerbations.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/904f884f2cedac3bc8311c15aeb35f7b"><gtr:id>904f884f2cedac3bc8311c15aeb35f7b</gtr:id><gtr:otherNames>Wang Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>56ddc99ba67758.90434904</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D92350B7-2FA4-426D-A164-4914128DFD8C</gtr:id><gtr:title>Differential effects of frozen storage on the molecular detection of bacterial taxa that inhabit the nasopharynx.</gtr:title><gtr:parentPublicationTitle>BMC clinical pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5bb6b48c6512eda568e8c90771ddf7e7"><gtr:id>5bb6b48c6512eda568e8c90771ddf7e7</gtr:id><gtr:otherNames>Kwambana BA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1472-6890</gtr:issn><gtr:outcomeId>pm_16537_27_21261963</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E5B5B383-3FD3-4864-A15C-CE2EE3B6485C</gtr:id><gtr:title>Association between pathogens detected using quantitative polymerase chain reaction with airway inflammation in COPD at stable state and exacerbations.</gtr:title><gtr:parentPublicationTitle>Chest</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba4addc1a896e7564698370d1fb5e822"><gtr:id>ba4addc1a896e7564698370d1fb5e822</gtr:id><gtr:otherNames>Barker BL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0012-3692</gtr:issn><gtr:outcomeId>545be04ccb17a7.65637413</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B0CA48DB-8696-4C8A-AB9E-D32700FAD969</gtr:id><gtr:title>Early acquisition and high nasopharyngeal co-colonisation by Streptococcus pneumoniae and three respiratory pathogens amongst Gambian new-borns and infants.</gtr:title><gtr:parentPublicationTitle>BMC infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5bb6b48c6512eda568e8c90771ddf7e7"><gtr:id>5bb6b48c6512eda568e8c90771ddf7e7</gtr:id><gtr:otherNames>Kwambana BA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1471-2334</gtr:issn><gtr:outcomeId>pm_16537_27_21689403</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D3A3212C-EC9E-4943-816E-04A39C20B7F0</gtr:id><gtr:title>Rapid replacement by non-vaccine pneumococcal serotypes may mitigate the impact of the pneumococcal conjugate vaccine on nasopharyngeal bacterial ecology.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb6e9d0c984ddf71b44ca96330dafa46"><gtr:id>bb6e9d0c984ddf71b44ca96330dafa46</gtr:id><gtr:otherNames>Kwambana-Adams B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5aa6647a3bece8.03062337</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801980</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>